Abstract -The inhibitory activities of microalgal extracts against the expression of three EBV antigens, latent membrane protein (LMP)1, Epstein-Barr nuclear antigen (EBNA)1 and Z Epstein-Barr reactivation activator (ZEBRA) were assessed by immunocytochemistry. The observation that the methanol extracts and their fractions from Ankistrodesmus convolutus, Synechococcus elongatus and Spirulina platensis exhibited inhibitory activity against EBV proteins in three Burkitt's lymphoma cell lines at concentrations as low as 20 µg/ml suggests that microalgae could be a potential source of antiviral compounds against EBV.
INTRODUCTION
Algae are a potential source of yet to be fully explored antiviral compounds. The sulfated polysaccharides from the red algae Porphyridium sp., and the blue green algae Spirulina platensis were found to inhibit the replication of herpes simplex virus-1 and -2 (HSV-1 and HSV-2), varicella zoster virus (VZV) and human immunodeficiency virus type 1 (HIV-1) (Hayashi et al., 1996; Huleihel et al. 2001; Huleihel et al., 2002; Barron et al., 2008) . The compounds griffithsin and fucoidan isolated from the red seaweed Griffithsia sp. and brown algae, respectively, were found to inhibit the entry of human immunodeficiency virus-1 (HIV-1) into host cells (Wang and Ng 2001; Hayashi et al., 2008; Hidari et al., 2008; Micewicz et al., 2010) . Despite many antiviral studies on algal compounds, there are few reports about the effects of these compounds against the Epstein-Barr virus (EBV).
The EBV is an etiological factor in Burkitt's lymphoma (BL) and other EBV-related malignancies, such as nasopharyngeal carcinoma, Hodgkin's disease and infectious mononucleosis (Rickinson and Kieff, 2006; Rezk and Weiss, 2007) . During latent infection, several of the nine viral latent gene products, such as the Epstein-Barr nuclear antigen
